India, Aug. 12 -- The Government of India issued the following news release:
The Central Drugs Standard Control Organization (CDSCO) and the Ministry of Health and Family Welfare have taken following regulatory and enforcement measures to prevent the entry of Not of Standard Quality (NSQ)/adulterated/spurious drugs in the market.
In order to assess the regulatory compliance of drug manufacturing premises in the country, the CDSCO, in collaboration with state regulators, initiated risk-based inspections of drug manufacturing and testing firms in December 2022. As of now, 905 units have been inspected, resulting in 694 actions being taken. These actions include Stop Production Orders (SPO), Stop Testing Orders (STO), license suspensions/can...